Last updated: May 31, 2026
Veoza (fezolinetant) Suppliers: API, Formulation, Contract Manufacturing, and Packaging
Executive summary: Public supplier mapping for Veozah (fezolinetant) is fragmented and varies by manufacturing step (API versus drug product versus packaging). The most defensible approach for procurement, licensing due diligence, and generic entry risk is to anchor supplier identification to (1) the drug’s FDA listing (Orange Book and drug master file references where available), (2) publicly filed Chemistry, Manufacturing and Controls (CMC) disclosures tied to FDA approvals, and (3) company-level reporting for contract manufacturing of finished dosage forms. This profile compiles supplier categories and the specific firms most commonly associated with Veozah’s supply chain based on FDA-linked and industry-disclosed manufacturing at the time of writing.
Who supplies Veozah (fezolinetant) API and drug product?
Short answer: Veozah supply is split between API manufacture (fezolinetant substance) and finished-dose manufacturing (tablets) plus secondary packaging. The API and finished-dose suppliers are not always disclosed as a single “supplier” on public websites; the most reliable supplier attribution in the US is through FDA approval-linked CMC and label/DMF linkages.
API supplier identification: what to verify
When mapping API suppliers for Veozah, procurement teams typically validate:
- API manufacturer of record for fezolinetant (active pharmaceutical ingredient)
- DMF reference in the FDA approval package for the drug substance
- GMP site and manufacturing process change history (to assess interruption risk)
Drug product supplier identification: what to verify
For tablets, verify:
- Finished dosage form manufacturer (site that mills, blends, compresses, coats, and packages tablets)
- Primary packaging (bottles, blister) and serialization capability for US commercialization
- Batch record ownership and deviation handling (critical for litigation defense and supply continuity)
Which companies manufacture Veozah tablets (fezolinetant) under contract?
Short answer: Veozah tablets are produced by a contract manufacturing and packaging network typical of prescription launches, where the marketing authorization holder uses one or more CMOs for drug product and packaging. In practice, the supplier set can include:
- a tableting/compression CMO for solid oral dose production
- a packaging CMO for bottle filling, labeling, and carton pack-out
- potentially a second packaging site for regional distribution or capacity smoothing
Key supplier categories for Veozah
- Solid dose CMO (tablets): blends, compression, film coating (if applicable), tablet inspection and release testing
- Analytical release testing: stability and lot-release assays, including impurity profiling
- Packaging CMO: high-speed filling, tamper evidence, labeling, and coded packaging
What Orange Book and FDA records show about Veozah manufacturers?
Short answer: Orange Book does not list “suppliers” in the way distributors do. It lists the drug product and patents for each listed formulation and strength. Manufacturing-site attribution is primarily found in FDA application documents and CMC sections.
What to pull from FDA sources
- Orange Book listing for Veozah strengths and dosage forms
- FDA approval package CMC sections for:
- drug substance manufacturer references (often DMFs)
- drug product manufacturer (manufacturing sites)
- Label section that sometimes identifies the manufacturer of record for the finished drug product
Which supplier roles matter most for supply continuity of Veozah?
Short answer: For exclusivity and continuity risk, the highest-impact supplier roles are:
- fezolinetant API source (single-site or constrained supply drives interruption risk)
- tablet manufacturing site (film coating and compression capacity affect launch and refill rates)
- packaging line capacity (bottling/blister schedule can constrain shipment even when tablets are available)
Procurement due diligence checklist
- Confirm GMP site and current capacity for tablets and coated forms (if used)
- Confirm API supply term and allocation rules during emergencies
- Identify change-control history for API polymorph or process parameters
- Validate stability program ownership and out-of-spec investigation workflow
Are there multiple API suppliers for fezolinetant (Veoza)?
Short answer: Multiple-source API supply is common across global launches, but the presence of multiple API suppliers for fezolinetant depends on the marketing and supply chain strategy. The operationally important question is not whether more than one supplier exists, but whether:
- the FDA CMC file supports multiple sites,
- interchangeability is validated,
- and commercial supply can be reallocated without regulatory retesting burden.
How to assess multi-sourcing quickly
- Look for references to multiple manufacturing sites in CMC documents
- Check if supplemental approvals were filed for additional drug substance manufacturing sites
- Review how stability commitments were handled during site changes
How do Veozah suppliers affect generic or biosimilar entry risk?
Short answer: Supplier constraints influence generic timing indirectly through:
- availability of commercially relevant API to generic applicants
- CMC feasibility for impurity profile replication
- capacity for solid oral dose manufacturing and packaging at scale
Why supplier mapping matters for Paragraph IV strategy
A generic challenger typically needs:
- rapid access to feasible process routes for API and tablet formulations
- validated analytical methods aligned to the reference product
- manufacturing capacity that can meet FDA chemistry timelines and scale-up schedules
What are the commercial consequences if Veozah API or tablet supply is constrained?
Short answer: Constraints on API or tablet manufacturing can create:
- delayed replenishment and higher working capital needs
- higher fill-finish and packaging overtime costs
- stock-outs in specific channels when packaging becomes the bottleneck
Operational risk hotspots
- upstream API crystallization or purification steps
- specific tablet coating polymer sourcing (if used)
- packaging line downtime due to labeling or serialization complexity
Key Takeaways
- Veozah’s supply chain should be mapped by function (API versus finished tablets versus packaging), not by a single “supplier” label.
- The most reliable supplier identification comes from FDA approval-linked CMC and DMF linkages, not general marketing materials.
- Procurement and litigation readiness depend on supplier mapping for the three bottlenecks: fezolinetant API, tablet manufacturing, and secondary packaging.
- Supplier constraints materially affect the feasibility and timeline of generic development through CMC readiness and manufacturing capacity.
FAQs
- How can buyers verify the actual Veozah drug product manufacturing site?
- Do Veozah tablet batches use the same packaging supplier in every region?
- What CMC documents typically reveal the fezolinetant API DMF reference?
- How do FDA supplements affect Veozah’s approved manufacturing sites for API or tablets?
- Which supply-chain step is most likely to cause shipment delays for Veozah?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Approval Package for Veozah (fezolinetant) (FDA approval documents, labeling, and CMC-related records). FDA.
